A carregar...
A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
The use of rituximab, an anti-CD20 mAb, in combination with chemotherapy is the current standard for the treatment of B-cell lymphomas. However, because of a significant number of treatment failures, there is a demand for new, improved therapeutics. Here, we designed a nanomedicine that crosslinks C...
Na minha lista:
| Publicado no: | Theranostics |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ivyspring International Publisher
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4440441/ https://ncbi.nlm.nih.gov/pubmed/26000056 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.12040 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|